| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322
 |
ABSTRACT |
|---|
 Top ABSTRACT IntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Experimental Design: Androgen and antiandrogen effects were evaluated on HIF-1
protein and HIF-1 transcriptional activation in human PCA cells.
Results: Dihydrotestosterone (DHT) activates HIF-1 nuclear protein expression in LNCaP cells but not in androgen receptor-negative PC-3 cells. HIF-1 expression is correlated with the transactivation of a hypoxia-responsive element-driven reporter gene and with the production of VEGF protein. The effect of DHT on HIF-1 was blocked by nonsteroidal antiandrogens, flutamide and bicalutamide. DHT does not affect HIF-1 mRNA levels but regulates HIF-1 protein expression through a translation-dependent pathway. PC-3 cells when incubated with increasing amounts of conditioned medium from LNCaP cells treated with DHT experienced a dose-dependent increase in HIF-1. This induction was not seen either when LNCaP cells were treated with flutamide or conditioned medium were pretreated with antibody to the epidermal growth factor (EGF). HIF-1 activation by DHT was blocked by LY294002, a potent inhibitor of the phosphatidylinositol 3'-kinase signaling pathway, whereas HIF-1 activation by EGF, as ligand, was not inhibited by flutamide. In contrast, HIF-2 protein was not affected by androgens or antiandrogens.
Conclusion: Androgens activate HIF-1, driving VEGF expression in androgen-sensitive LNCaP cells. This regulation is mediated through an autocrine loop involving EGF/phosphatidylinositol 3'-kinase/protein kinase B, which in turn activate HIF-1 and HIF-1-regulated gene expression. Therapeutic actions of antiandrogens in PCA include inhibition of HIF-1 function.
|
Introduction |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
, platelet-derived growth factor, acidic and basic fibroblast growth factors, insulin-like growth factor I, and matrix metalloproteinases (2
, 3)
. VEGF is a critical one, which can be produced by many tumor cell types (4)
. Elevated expression of VEGF has been shown in human and animal models of PCA (5
, 6)
. VEGF expression is regulated by various growth factors, cytokines, estrogen, progesterone, and glucocorticoids (7, 8, 9, 10, 11, 12, 13, 14)
. Hypoxia is thought to be the most potent stimulus for VEGF (15, 16, 17, 18)
, and its expression is transcriptionally regulated by HIF-1 (19, 20, 21, 22)
. Androgens regulate VEGF content in normal and malignant prostate cells (23, 24, 25, 26)
. However, the mechanisms underlining the above observations are not clearly defined.
HIF-1 is a critical, genome-wide transcription regulator identified for O2 homeostasis responsive to hypoxic stress. HIF-1 controls the expression of >40 genes including VEGF, of which the protein products are involved in angiogenesis, erythropoiesis, glycolysis, and invasion (27)
. HIF-1 is a heterodimer composed of HIF-1 and HIF-1ß subunits, which are basic helix-loop-helix-Per/Arnt/Sim domain proteins. HIF-1ß is constitutively expressed, whereas the expression of HIF-1 is maintained at low levels in most cells under normoxic conditions. Under hypoxic conditions, HIF-1 escapes proteasomal degradation and then translocates to the nucleus. The former process results from inhibiting the activity of oxygen-dependent prolyl hydroxylases that modify residues 564 and 402 (28)
, and the latter process is mediated by nuclear localization signals. This enzymatic modification of HIF-1 is required for the binding of von Hippel-Lindau protein, which is the recognition component of an E3 ubiquitin-protein ligase that targets HIF-1 for proteasomal degradation. In contrast to the oxygen-dependent regulation of HIF-1 degradation, we and others reported that growth factor stimulation induces HIF-1 protein synthesis via a signal transduction pathway leading from receptor tyrosine kinases to PI3K to the serine/threonine kinases AKT and FRAP (mTOR; Refs. 29, 30, 31, 32, 33, 34
).
Up-regulated HIF-1 expression has been observed in >70% of cancers including PCA as compared with adjacent normal tissues (35
, 36)
, and is likely achieved through both epigenetic mechanisms (intratumoral hypoxia) and genetic alterations (mutations in tumor suppressor genes and oncogene activation; Ref. 29
). Overexpression of HIF-1 or HIF-1-dependent genes is associated with aggressive behavior in human cancers in vitro as well as in clinical specimens (35
, 37, 38, 39, 40, 41, 42, 43, 44, 45)
. Hypoxic regions exist in human prostate carcinoma and increasing levels of hypoxia are associated with higher clinical stages (46)
. In mouse xenograft models, tumor growth and angiogenesis are inhibited by small molecules and genetic strategies that disrupt HIF-1 activity but are stimulated by HIF-1 overexpression (27
, 47)
.
We tested the hypothesis that an antiangiogenic effect of antiandrogens in androgen-responsive PCA cells can be regulated by blocking HIF-1 transcriptional pathway. We found that DHT stimulates HIF-1 protein expression, HIF-1 transcriptional activity, and VEGF production in LNCaP cells, whereas flutamide reduced these effects. Our experiments indicate that androgenic induction of HIF-1 protein expression and function are regulated in part through an autocrine loop mechanism involving the PI3K/AKT pathway in PCA cells.
|
Materials and Methods |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Reagents and Antibodies.
DHT and flutamide were obtained from Sigma-Aldrich (St. Louis, MO). CHX was from BIOMOL Research Laboratories Inc. (Plymouth Meeting, PA). LY294002 was purchased from Alexis Biochemicals (San Diego, CA). Human recombinant EGF was purchased from Life Technologies, Inc. (Rockville, MD). R1881 was from Perkin-Elmer, Inc. (Boston, MA). Bicalutamide (Casodex) was a generous gift from Dr. Leland W. Chung (Emory University, Atlanta, GA). Purified mouse monoclonal anti-HIF-1 antibody was obtained from BD Transduction Laboratories (Lexington, KY). Polyclonal human antibody against HIF-2 was purchased from Novus Biologicals (Littleton, CO). Antibodies against human AR, actin, and VEGF (A-20) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal human antibody to human TOPO-I was purchased from TopoGEN (Columbus, OH). The monoclonal antibody to rhEGF was purchased from R & D Systems, Inc. (Minneapolis, MN). The PhosphoPlus AKT (Ser473) Antibody kit for analysis of the phopholylation status of AKT and antibody to phospho-p44/42 MAPK (Thr202/Tyr204) were purchased from Cell Signaling Technology, Inc. (Beverly, MA). Secondary antibodies were horseradish peroxidase-conjugated and purchased from Amersham Pharmacia Biotech (Piscataway, NJ).
Hormonal Treatment of LNCaP Cells.
Only a low passage number (up to 10) of LNCaP cells were used. Cells were seeded in either six-well or 100-mm cell culture dishes and grown in RPMI 1640 containing 10% fetal bovine serum until 50% confluence. The medium was then replaced with phenol-red free RPMI 1640 containing 10% charcoal stripped serum (androgen-free medium). After 24 h, the androgen-free medium was refreshed and 1 nM DHT (dissolved in 100% ethanol), 1 µM flutamide (dissolved in DMSO), or vehicle (0.1% ethanol and/or 0.1% DMSO) was added. The medium was changed at 2-day intervals.
Protein Isolation and Western Blot Analysis.
Cells were washed twice with ice-cold PBS and then harvested, scraped into ice-cold PBS, and pelleted by centrifugation at 500 x g for 5 min at 4°C. NE and CE were prepared as described previously (48)
. Briefly, the packed cells were resuspended in 10 mM Tris HCl (pH 7.5), 1.5 mM MgCl2, and 10 mM KCl freshly supplemented with 2 mM DTT, 0.4 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml apportioning, 2 µg/ml pepstatin, and 1 mM Na3VO4. Cells were kept on ice for 10 min. Nuclei were pelleted by centrifugation at 17,000 x g for 10 min at 4°C. The CE was kept, and the pellet was resuspended in 0.5 M NaCl, 20 mM Tris HCl (pH 7.5), 20% glycerol, and 1.5 mM MgCl2 freshly supplemented with the protease and phosphatase inhibitors listed above, and then rotated for 30 min in the cold room. The NE was cleared by centrifugation at 20,000 x g for 30 min at 4°C.
Proteins (30–60 µg/lane) from CEs or NEs were resolved by 7.5% SDS-PAGE, electrotransferred to nitrocellulose membrane, and incubated with the primary antibody. Immunoreactivity was visualized by incubating the membrane with horseradish peroxidase-conjugated secondary antiserum, followed by the treatment with enhanced chemiluminescence reagent (Amersham Biosciences, Piscataway, NJ). For detection with another antibody, the membranes were stripped using a restore Western blot stripping buffer (Pierce, Rockford, IL) and reprobed with the desired antibody. TOPO-I and actin antibodies were used as a loading control for NE and CE, respectively.
VEGF and PSA Measurement.
LNCaP culture media were collected, centrifuged to remove cellular debris, and stored at -70°C until assayed for VEGF or PSA. VEGF assay was performed using a commercially available ELISA kit (R & D Systems, Inc.). PSA protein levels were determined using Microparticle Enzyme Immunoassay (Abbott IMx PSA assay; Abbott Laboratories, Abbott Park, IL). Results between wells were standardized according to the amount of VEGF or PSA per total protein per well as measured in cell lysates and expressed as pg of VEGF protein per ml supernatant and ng of PSA protein per ml supernatant.
Transient Transfections and Reporter Gene Assay.
LNCaP cells growing in six-well culture plates were transfected in triplicate with 1 µg/well of reporter plasmid (pBI-GL V6L) containing HREs from the VEGF gene using GenePorter transfection reagent (Gene Therapy Sys, Inc., San Diego, CA) as described (49
, 50)
. After 5 h of transfection, the cells were allowed to recover overnight in androgen-free medium. The cells were then washed twice with PBS, and replenished with androgen-free medium and vehicle or reagent as indicated in the figure legends. Duplicate sets of transfected cell culture dishes were then separated and incubated either under normoxic or hypoxic conditions for 16 h. Luciferase activity was measured with commercial kit TROPIX (Bedford, MA) using a BMG Labtechnologies LUMIstar Galaxy luminometer and following the manufacturer’s instructions. Arbitrary Luciferase activity units were normalized to the amount of protein in each assay point. Protein concentration was determined using a BCA protein assay kit (Pierce).
Isolation and Analysis of RNA.
Total RNA was isolated using TRIzol Reagent (Life Technologies, Inc.) and was subjected (15 µg/sample) to Northern blotting using human HIF-1 cDNA probe (593-bp HindIII/MspI fragment) as described (51)
or GAPDH and ß-actin probes (Ambion, Inc., Austin, TX).
Data Analysis.
Experiments presented in the figures are representative of three or more different repetitions. Quantification of band densities was performed using the public domain NIH Image (version 1.61). Statistical analysis was performed using a one-way ANOVA test (P < 0.05 was considered statistically significant).
|
Results |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Protein and HIF-1 Activity. and HIF-2 protein expression in LNCaP cells starting at 24 h after the culture medium was changed to androgen-free medium under normoxic conditions (Fig. 1A)
. Treatment with DHT showed an 
4-fold increase in HIF-1 after 24 h, which then increased to a maximum 10-fold increase after 48 h. Additional incubation resulted in a gradual decrease in the levels of the protein. The time-dependent changes in expression of HIF-1 in LNCaP cells were similar to those of PSA (Fig. 1B)
and VEGF (Fig. 1C)
in the culture medium, but all were still higher in the presence of DHT than control and flutamide at each time point. VEGF protein expression in cytoplasmic fraction was induced by DHT as well. Changes in nuclear HIF-2 protein levels were minimal compared with HIF-1 (Fig. 1A)
. Clinically relevant in vitro concentrations of flutamide were selected for testing. Fultamide (1 µM) inhibited the induction of HIF-1 protein by DHT (Fig. 2A)
. To measure the transcriptional activity of HIF-1, we used a reporter gene assay (Fig. 2B)
. LNCaP cells were transiently transfected with a construct containing Luciferase gene under the control of the HRE from the VEGF promoter (49)
. Consistent with the changes in HIF-1 protein levels, the hypoxia-induced HIF-1 transcriptional activation was enhanced 2-fold by DHT and was inhibited by flutamide (Fig. 2B)
. Because HIF-1 protein levels are very low in LNCaP cells under normoxia, HIF-1 transcriptional activity under normoxia measured by the reporter gene assay was undetectable (Fig. 2B)
. HIF-1 was also induced by low concentration (0.1 nM) of R1881, a nonmetabolizable synthetic androgen, and this induction was inhibited by the antiandrogen bicalutamide (Casodex; Fig. 2C
).
|
|
through a Translation-dependent Pathway. induction in response to androgen treatment, we investigated the effect of DHT and flutamide on the amount of HIF-1 mRNA. LNCaP cells were treated with DHT or flutamide, total RNA was extracted, and Northern blot analysis was performed using a HIF-1 cDNA probe (Fig. 3A)
. We found neither DHT nor flutamide treatment changed significantly HIF-1 mRNA levels, suggesting that androgens do not regulate HIF-1 mRNA transcription. In contrast, the amount of GAPDH mRNA, which is a HIF-1 regulated gene (52, 53, 54)
, was increased by DHT treatment suggesting the coactivation of HIF-1 transcriptional function in response to DHT (Fig. 3A)
. To analyze the effect of androgen on HIF-1 protein synthesis, we performed a time course of HIF-1 disappearance in the presence of the protein translation inhibitor, CHX (Fig. 3B)
. Within 15 min of CHX incubation HIF-1 protein fell to undetectable levels after DHT treatment. We compared the effect of DHT on HIF-1 with CoCl2 and EGF. CoCl2 mimic hypoxia and are known to block HIF-1 degradation but have no effect on HIF-1 synthesis (55)
. As expected in cells exposed to CoCl2, HIF-1 level remained almost stable for 60 min, despite the lack of ongoing protein synthesis (Fig. 3B)
. On the other hand, EGF has been shown in previous studies to regulate HIF-1 through PI3K/AKT pathway mainly by enhancing the efficiency of HIF-1 mRNA translation (29, 30, 31)
. Similar to EGF, the induction of HIF-1 by DHT was completely blocked by CHX within 15 min (Fig. 3C)
. Together, these results suggest that androgens increases HIF-1 levels through a translation-dependent pathway.
|
through an Autocrine PI3K/AKT-dependent Pathway. is mediated directly by the activation of the AR or is a consequent event of AR-downstream proliferative effects involving growth factors and their signaling pathways. To test that the effect of androgens on HIF-1 is mediated by the AR, we treated the hormone-insensitive PC-3 cells with DHT and flutamide. Neither DHT nor flutamide affected the steady state levels of HIF-1 protein in direct comparison of PC-3 cells with LNCaP cells (Fig. 4A)
. This result suggests that the effect of androgens on HIF-1 is mediated by the activation of the AR itself by androgens.
|
is regulated by extracellular peptide growth factors under normoxic conditions (29, 30, 31)
, we hypothesized that activation of AR could involve pathways upstream to HIF-1, such as PI3K/AKT signaling pathway. To test this hypothesis, we treated PC-3 cells with conditioned medium from LNCaP cells treated with vehicle, DHT, or flutamide. As shown in Fig. 4B
, the "conditioned" culture medium taken from LNCaP treated with DHT induced a modest increase in HIF-1 protein levels, whereas flutamide inhibited HIF-1 in 70% compared with the control (Fig. 4B)
. This result suggests that conditioned medium contained soluble factors such as growth factors, secreted by LNCaP cells that effected HIF-1 levels in PC-3 cells. It seems that these "factors" were also present in the conditioned medium taken from control LNCaP cells, because HIF-1 levels were modestly enhanced by conditioned medium from DHT-treated cells but were inhibited by flutamide to an extent lesser than the control (Fig. 4B)
. The effect of conditioned medium from both untreated and DHT-treated LNCaP cells on HIF-1 was dose-dependent (Fig. 4
C, top panel). Investigators have found that androgen stimulation of PCA cells in vitro leads to increased levels of secreted growth factors and their receptors including EGF (56
, 57)
. On the basis of these reported findings, we anticipated that one of the soluble factors in LNCaP conditioned medium and that affects HIF-1 in PC-3 cells could be EGF. As depicted in Fig. 4C
(bottom panel) HIF-1 levels in PC-3 cells incubated with conditioned medium from LNCaP cells treated with DHT were inhibited by increasing concentration of a blocking monoclonal antibody to rhEGF that neutralizes EGF bioactivity (R & D Systems, Inc.). This result suggests that a significant part of HIF-1 induction in PC-3 cells by LNCaP conditioned medium is derived from EGF activity. As a control for androgen response we measured VEGF (Fig. 4D)
and PSA (Fig. 4E)
levels in LNCaP conditioned medium used in PC-3 cells.
To test whether the up-regulation of HIF-1 by DHT is dependent on PI3K, we studied the effect of two inhibitors of tyrosine kinase receptor/PI3K, LY294002, and wortmannin in LNCaP cells. LY294002 completely blocked HIF-1 protein in DHT-treated LNCaP cells similar to those treated with EGF (Fig. 5A)
as well as inhibited the DHT transactivation of HIF-1-dependent reporter gene (Fig. 5B)
. Similar results were obtained by wortmannin (data not shown). Interestingly, flutamide failed to inhibit HIF-1 levels after EGF treatment (Fig. 5A)
suggesting that the effect of AR activation on HIF-1 is upstream to EGF activity. To additionally confirm that the effect of LY294002 in LNCaP cells is because of PI3K pathway, we studied the phosphorylation status of AKT forms. As was shown previously, AKT was constitutively activated as a result of a frameshift mutation in the PTEN gene (58)
, but its phosphorylation was totally blocked by LY294002 in LNCaP cells in comparison with NIH-3T3 cells as a control (Fig. 5C
, top panel). Neither DHT nor flutamide affected the activated AKT (Fig. 5C
, bottom panel). On the other hand, EGF enhanced the activation of AKT, which was entirely blocked by the addition of LY294002 but not by flutamide (Fig. 5C
, bottom panel). Furthermore, LY294002 blocked the phosphorylation of AKT in the presence of DHT, indicating that the inhibitory effect of LY294002 on DHT-induced HIF-1 is mediated through PI3K/AKT pathway. The effect of LY294002 was specific on PI3K because it had no effect on the EGF-activated forms of MAPK (Fig. 5D)
. In summary, DHT induces HIF-1 by increasing secretion of at least EGF, which through an autocrine mechanism activates PI3K/AKT pathway.
|
|
Discussion |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Our results indicate that androgens and antiandrogens regulate HIF-1 expression, HIF-1 transcriptional activity leading to the secretion of VEGF (Figs. 1
and 2
). HIF-2 was not affected by androgens or antiandrogens in the LNCaP system. DHT and flutamide did not affect HIF-1 mRNA levels (Fig. 3A)
. Using the protein translation inhibitor CHX, we found that the induction of HIF-1 by DHT is likely dependent on a translation pathway rather than affecting the rate of HIF-1 protein stability or degradation (Fig. 3B)
. Given HIF-1 signaling by FRAP/mTOR (29, 30, 31)
, we suspect that DHT via FRAP/mTOR is increasing the rate of ribosomal recruitment to mRNA and, thus, enhancing synthesis of new HIF-1 protein molecules (27)
.
HIF-1 regulation was restricted only to androgen-responsive LNCaP cells but not to the hormone-irresponsive PC-3 cells. Interestingly, when PC-3 cells were treated with increasing amounts of conditioned medium from LNCaP cells, HIF-1 protein was induced in a dose-dependent manner (Fig. 4C)
. Most importantly, conditioned medium from LNCaP cells treated with flutamide inhibited HIF-1 expression compared with the other conditioned medium (Fig. 4B)
. This implied that the LNCaP cells secrete factors under the influence of the androgen and that these factors, rather than the androgen, resulted in the increased expression of HIF-1. Because HIF-1 expression, particularly under normoxic conditions, is under the control of the receptor tyrosine kinase/PI3K/AKT signaling pathway (29, 30, 31, 32)
, we anticipated that part of the factors effecting HIF-1 levels in the conditioned medium are likely growth factors such as EGF. Indeed, the stimulatory effect of the conditioned medium from LNCaP cells on HIF-1 in PC-3 cells was inhibited when conditioned medium were pretreated with antibody to rhEGF (Fig. 4B)
. These results suggest that an extracellular autocrine growth factor effect is involved in DHT stimulation of HIF-1. Moreover, we observed that the DHT-induced HIF-1 and HIF-1 activity is totally inhibited by LY294002, whereas the EGF-induced HIF-1 was not affected by flutamide (Fig. 5)
. These responses were accordingly correlated with the phosphorylation status of AKT.
Hydroxyflutamide, an active metabolite of flutamide has been found previously to enhance AR translocation and to promote AR transcriptional activity in LNCaP cells as an AR agonist, because there is a mutation in the LNCaP AR gene (59
, 60)
. As a positive control, we found that flutamide induced a small increase of PSA expression at 48-h time point, whereas DHT enhanced PSA expression by >3-fold (Fig. 1B)
. A similar dynamic pattern of expression was also observed on VEGF (Fig. 1C)
and on HIF-1 (Fig. 1A)
at the 48-h time point. Interestingly, when 1 µM flutamide was combined with 1 nM DHT, flutamide had an antagonistic effect on HIF-1, probably by competing with DHT as a weak agonist (Fig. 2)
. These effects are similar to what was reported previously with EGF; androgens induce a marked increase of extracellular EGF secretion, whereas this induction is blocked by the antiandrogen hydroxyflutamide in LNCaP cells (56)
. In addition to the increase in EGF release after androgen stimulation, both EGFR number and receptor binding affinity are also increased (57)
. Furthermore, EGF was reported recently to greatly enhance the expression of VEGF in androgen-independent PCA cell lines, PC-3 and DU-145 cells (61)
. Taken together, our results and findings published previously lead us to propose a new model explaining the transcription factor cross-talk between AR and HIF-1 intracellular signaling pathways (Fig. 6)
. Androgen ligand would activate the AR and lead to proliferative effects on LNCaP cells, and consequently stimulates growth factor secretory responses (62
, 63)
including growth factors and their receptors such as EGF (56
, 57)
. As a result, these growth factors like EGF, bind via cognate receptors activating tyrosine kinase/PI3K/AKT/FRAP pathway and enhance HIF-1 protein synthesis under normoxic conditions as described previously in PCA and other in vitro systems (29, 30, 31, 32)
. As a consequence, activation of HIF-1 drives the expression of genes involved in angiogenesis, survival, energy metabolism, and proliferation (27
, 64)
.
|
or HIF-1 upstream pathways such as blockade of EGFR (65)
especially in androgen-independent PCA. This is supported by data reported recently showing the antiangiogenic and antitumor activity of EGFR blockade either by the anti-EGFR antibody ImClone C225 (IMC-C225; Ref. 66
) or the selective EGFR tyrosine kinase inhibitor ZD1839 (67)
.
Androgen regulation of HIF-1 occurs under normoxic conditions but can be additionally enhanced under hypoxia (Fig. 2B
; Fig. 4D
). This provides additional evidence that synergistic interactions exist between PI3K/AKT pathway activation and hypoxic pathway activation in PCA to regulate HIF-1 and drive angiogenesis (29)
. Antiandrogens are major antineoplastic drugs for advanced PCA. Our data suggest part of their clinical activity could involve reduction in HIF-1 transcriptional activation of VEGF and, thus, reducing angiogenic potential of androgen-sensitive clones.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by NIH Prostate Cancer Specialized Programs of Research Excellence Grant CA-58236 (to J. W. S.), Avon Foundation (to J. W. S. and H. Z.), and CaP CURE Foundation (to J. W. S.). 
2 To whom requests for reprints should be addressed, at 1365 Clifton Road, NE, Suite B4100, Atlanta, GA 30322. Phone: (404) 778-5177; Fax: (404) 778-5048; E-mail: jonathan_simons{at}emoryhealthcare.org
3 The abbreviations used are: PCA, prostate cancer; VEGF, vascular endothelial growth factor; HIF-1, hypoxia-inducible factor 1; EGF, epidermal growth factor; PI3K, phosphatidylinositol 3'-kinase; DHT, dihydrotestosterone; CHX, cycloheximide; R1881, methyltrienolone; AR, androgen receptor; TOPO-I, topoisomerase I; rhEGF, recombinant human EGF; MAPK, mitogen-activated protein kinase; GAPDH, glyceraldehydes-3-phosphate dehydrogenase; PSA, prostate-specific antigen; HRE, hypoxia response element; AKT, protein kinase B; mTOR, mammalian target of rapamycin; FRAP, FKBP (FK506-binding protein) and rapamycin-associated protein; EGFR, epidermal growth factor receptor; NE, nuclear extract; CE, cytoplasmic extract.
Received 11/13/02; revised 1/24/03; accepted 2/ 4/03.
|
REFERENCES |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545, 2000. (HIF-1) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol., 21: 3995-4004, 2001.. HIF-2, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res., 61: 7349-7355, 2001. by insulin and interleukin-1ß involves the phosphatidylinositol 3-kinase pathway. FEBS Lett., 512: 157-162, 2002.[CrossRef][Medline]
nor sufficient for HIF-1-dependent target gene transcription. J. Biol. Chem., 277: 15162-15170, 2002. in common human cancers and their metastases. Cancer Res., 59: 5830-5835, 1999. and HIF-2 in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 157: 411-421, 2000. during breast carcinogenesis. J. Natl. Cancer Inst., 93: 309-314, 2001. in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer (Phila.), 92: 165-171, 2001.[CrossRef][Medline]
in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res., 7: 1661-1668, 2001. is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res., 60: 4693-4696, 2000. and 2 in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer, 85: 881-890, 2001.[CrossRef][Medline]
: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61: 2911-2916, 2001. protein via the proteosome pathway in prostate cancer cells. Cancer Res., 62: 2478-2482, 2002. in rat and human prostate cancer. Cancer Res., 58: 5280-5284, 1998.Commentary
, a Gender Independent Transcription Factor
This article has been cited by other articles:
|
|
 |
|
  K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen Proliferation of Immature Tumor Vessels Is a Novel Marker of Clinical Progression in Prostate Cancer Cancer Res., June 1, 2009; 69(11): 4708 - 4715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Buteau-Lozano, G. Velasco, M. Cristofari, P. Balaguer, and M. Perrot-Applanat Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism J. Endocrinol., February 1, 2008; 196(2): 399 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Rudolfsson and A. Bergh Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1{alpha} J. Endocrinol., January 1, 2008; 196(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chouinard, O. Barbier, and A. Belanger UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 Enzymes Are Major Determinants of the Androgen Response in Prostate Cancer LNCaP Cells J. Biol. Chem., November 16, 2007; 282(46): 33466 - 33474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-J. Hsiao, M.-Y. Lu, F.-Y. Chiang, S.-J. Shin, Y.-D. Tai, and S.-H. H. Juo Vascular endothelial growth factor gene polymorphisms in thyroid cancer J. Endocrinol., November 1, 2007; 195(2): 265 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Mukhopadhyay, B. Cinar, L. Mukhopadhyay, M. Lutchman, A. S. Ferdinand, J. Kim, L. W. K. Chung, R. M. Adam, S. K. Ray, A. B. Leiter, et al. The Zinc Finger Protein Ras-Responsive Element Binding Protein-1 Is a Coregulator of the Androgen Receptor: Implications for the Role of the Ras Pathway in Enhancing Androgenic Signaling in Prostate Cancer Mol. Endocrinol., September 1, 2007; 21(9): 2056 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Milosevic, P. Chung, C. Parker, R. Bristow, A. Toi, T. Panzarella, P. Warde, C. Catton, C. Menard, A. Bayley, et al. Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response Cancer Res., July 1, 2007; 67(13): 6022 - 6025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Kazi and R. D. Koos Estrogen-Induced Activation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor Expression, and Edema in the Uterus Are Mediated by the Phosphatidylinositol 3-Kinase/Akt Pathway Endocrinology, May 1, 2007; 148(5): 2363 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Horii, Y. Suzuki, Y. Kondo, M. Akimoto, T. Nishimura, Y. Yamabe, M. Sakaue, T. Sano, T. Kitagawa, S. Himeno, et al. Androgen-Dependent Gene Expression of Prostate-Specific Antigen Is Enhanced Synergistically by Hypoxia in Human Prostate Cancer Cells Mol. Cancer Res., April 1, 2007; 5(4): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ben-Shoshan, S. Amir, D. T. Dang, L. H. Dang, Y. Weisman, and N. J. Mabjeesh 1{alpha},25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells Mol. Cancer Ther., April 1, 2007; 6(4): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K S Kimbro and J W Simons Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, O. W. Moe, J. A. Garcia, and C. C. W. Hsia Regulated expression of hypoxia-inducible factors during postnatal and postpneumonectomy lung growth Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L880 - L889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Moeller, A. M. Dumitrescu, and S. Refetoff Cytosolic Action of Thyroid Hormone Leads to Induction of Hypoxia-Inducible Factor-1{alpha} and Glycolytic Genes Mol. Endocrinol., December 1, 2005; 19(12): 2955 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Boddy, S. B. Fox, C. Han, L. Campo, H. Turley, S. Kanga, P. R. Malone, and A. L. Harris The Androgen Receptor Is Significantly Associated with Vascular Endothelial Growth Factor and Hypoxia Sensing via Hypoxia-Inducible Factors HIF-1a, HIF-2a, and the Prolyl Hydroxylases in Human Prostate Cancer Clin. Cancer Res., November 1, 2005; 11(21): 7658 - 7663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Wenger, D. P. Stiehl, and G. Camenisch Integration of Oxygen Signaling at the Consensus HRE Sci. Signal., October 18, 2005; 2005(306): re12 - re12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Kazi, J. M. Jones, and R. D. Koos Chromatin Immunoprecipitation Analysis of Gene Expression in the Rat Uterus in Vivo: Estrogen-Induced Recruitment of Both Estrogen Receptor {alpha} and Hypoxia-Inducible Factor 1 to the Vascular Endothelial Growth Factor Promoter Mol. Endocrinol., August 1, 2005; 19(8): 2006 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Titus, C. W. Gregory, O. H. Ford III, M. J. Schell, S. J. Maygarden, and J. L. Mohler Steroid 5{alpha}-Reductase Isozymes I and II in Recurrent Prostate Cancer Clin. Cancer Res., June 15, 2005; 11(12): 4365 - 4371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colombel, S. Filleur, P. Fournier, C. Merle, J. Guglielmi, A. Courtin, A. Degeorges, C. M. Serre, R. Bouvier, P. Clezardin, et al. Androgens Repress the Expression of the Angiogenesis Inhibitor Thrombospondin-1 in Normal and Neoplastic Prostate Cancer Res., January 1, 2005; 65(1): 300 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Karanam and C. S. Moreno CONFAC: automated application of comparative genomic promoter analysis to DNA microarray datasets Nucleic Acids Res., July 1, 2004; 32(suppl_2): W475 - W484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le and A. J. Giaccia HIF-{alpha}, a Gender Independent Transcription Factor Clin. Cancer Res., July 1, 2003; 9(7): 2391 - 2393. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
